22 February 2021
Visiongain has published a new report on Retinal Disorder Treatment Market Report 2021-2031: Forecasts By Disease Indication (Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema, Retinal Vein Occlusion, and Others), By Therapeutic Class (Anti-VEGF Agents, Anti-inflammatory Drugs, and Others), By Dosage Form (Gels, Eye Solutions, Capsules & Tablets, Eye Drops, Ointments, and Others), By Patient Demographics (Adults, Geriatric, and Pediatric), By End User (Hospitals, Homecare, Specialty Clinics, and Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies) PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.
Global Retinal Disorder Treatment market was valued at US$ xx Million in 2020 and is projected to reach at a market value of US$ xx Million by 2031. North America dominated the global Retinal Disorder Treatment market and is projected to witness CAGR of XX% during the first half of the forecast period i.e. 2021 to 2031.
COVID-19 Impact on Retinal Disorder Treatment Market
COVID-19 impact through different recovery models such as V-shaped, U-shaped, W-shaped, and L-shaped; has been taken into consideration while estimating and forecasting the Retinal Disorder Treatment market. Different recovery scenarios are also included in the report for all the segments and regions/nation. The recovery scenarios based on which market has been forecasted and analysed herein the report are mentioned below:
Increasing Prevalence of Retinal Disorders
Retinal Disorders prevalence has increased very rapidly as compared to the last few years and it is expected that retinal disorders prevalence will increase during the forecast period. According to Genentech, USA Inc. that approximately 200,000 new cases of Wet Age-Related Macular Degeneration (Wet AMD) use to be identified each year in the United States and approximately 7.7 million Americans are suffering from diabetic retinopathy. And which is expected to increase by 11.3 million by 2030. Increasing retinal disorders cases is creating a huge demand for the retinal disorders treatment. Due to which Increasing prevalence of retinal disorders is working as a driver for the retinal disorders treatment market.
Increasing Geriatric Population around the World
An increasing in geriatric population is suffering from various retinal disorders including diabetic retinopathy and age-related degeneration (AMD). All regions are facing a huge increase in the number of geriatric populations. For instance: According to the United Nations, Department of Economic and Social Affairs, the Population Division geriatric population (persons aged 65 or over) was 702.9 million in 2019. Geriatric population is at high risk of retinal disorders and requires anti-VEGF agents, anti-inflammatory drugs, and others for treatment. Rapid increase in the number of the geriatric population around the globe is also increasing demand for retinal disorders treatment around the world. Due to which increasing geriatric population around the world is working as a driver for the retinal disorders market.
Increasing Strategic initiatives in retinal disorders treatment Drugs
Manufactures present in the market are taking various strategic initiatives in order to increase their revenue generation in the market, strategic initiatives such as mergers & acquisitions, product launches and press conference & events. These strategic initiatives are helping manufacturers in the market to increase their revenue generation due to this reason increasing strategic initiatives in the retinal disorders treatment market is creating new opportunities as a driver for the retinal disorders treatment market.
Top companies (Santen Pharmaceutical Co., Ltd., Regeneron Pharmaceuticals, Inc., and F. Hoffmann-La Roche Ltd.) constitute more than XX% share of the global Retinal Disorder Treatment market. Other companies profiled in the report include: Pfizer, Inc., Allergan plc, Shire (Takeda Pharmaceutical Company Limited), Bayer AG, Graybug Vision, Inc., Novartis AG and Acucela Inc. (Kubota Pharmaceutical Holdings Co., Ltd.). Some of the key developments are listed below:
● In 2020, Ocugen has received fourth Orphan Drug Designation (ODD) from FDA granted for OCU400 in the treatment of PDE6B gene mutation-associated retinal diseases. The launch will help the company to expand retinal disorder treatment and widened revenue generation from market focused product portfolio.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
14 July 2021
Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.